Cardiac Amyloidosis

ASNC is the premier source for education and quality in the rapidly expanding area of cardiac amyloidosis. Through its initiatives and partnerships, ASNC is supporting a collaborative approach to awareness, early diagnosis and effective treatments that will save lives and improve quality of life for patients with CA. As the medical society focused on nuclear cardiology, ASNC is uniquely qualified to provide education, information and advocacy that ensures appropriate referrals for Tc-99m PYP imaging; supports high-quality testing, interpretation and reporting of Tc-99m PYP imaging by imagers; and encourages fair reimbursement of Tc-99m PYP services and approval of CA treatment agents.

Live Programs

Case-Based Approach to Diagnosis and Management of Cardiac Amyloidosis 
Palm Harbor, FL
Friday, April 12, 2019 | 7:30 am – 11:30 am
CME available

NEW CME Webinar Series

Lessons in Transthyretin Cardiac Amyloidosis

Webinar 1: Contemporary Diagnosis and Risk Assessment in Transthyretin Cardiomyopathy​
Thursday, February 21, 2019
Faculty: Sharmila Dorbala, MD, MPH, FASNC, Chair, and Ronald M. Witteles, MD, Co-moderators. Mazen Hanna, MD and Martha Grogan, MD, Presenters
Credit: 1 AMA PRA Category 1 Credits^TM (CME) for Physicians
Fee: ASNC Members, free; Non-members, $75
This activity is supported by an educational grant from Pfizer.
Archived in our Learning Center

Webinar 2: State of the Art Imaging in Cardiac Amyloidosis
Wednesday, March 20, 2019
noon EST
Faculty: Sharmila Dorbala, MD, MPH, FASNC, Chair, and Jamieson Bourque, MD, Co-moderators. Frederick Ruberg, MD and Wael Jaber, MD, Presenters
Credit: 1 AMA PRA Category 1 Credits^TM (CME) for Physicians
Fee: ASNC Members, free; Non-members, $75
This activity is supported by an educational grant from Pfizer.
Archived in our Learning Center

Webinar 3: Cardiac Amyloidosis Treatments Today, Emerging Treatments for Tomorrow
Date: May 24, 2019
Time: noon EDT
Faculty: Sharmila Dorbala, MD, MPH, FASNC, Chair, and Prem Soman, MD, MASNC, Co-moderators. Rodney Falk, MD and Mathew Maurer, MD, Presenters
Credit: 1 AMA PRA Category 1 Credits^TM (CME) for Physicians
Fee: ASNC Members, free; Non-members, $75
This activity is supported by an educational grant from Pfizer.

Guidelines

• Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis - 2018
• ASNC imaging guidelines for nuclear cardiology procedures - 2017

Practice Points 

•  ^99m Technetium-Pyrophosphate Imaging for Transthyretin Cardiac Amyloidosis- 2019 (Open-access for a limited time- Join ASNC to gain access to all our practice points and other member-only resources)

Journal of Nuclear Cardiology Articles

• Imaging cardiac amyloidosis: Patient Page- 2018

ASNC Blog Posts

• Cardiac Amyloidosis Doesn't Have to Be Intimidating: A Primer on Diagnosis by Noel Dasgupta, MD

Other Articles

• Alexander KM, Singh A, Falk RH. Novel pharmacotherapies for cardiac amyloidosis. Pharmacol Ther. 2017;180:129-138.
• Bokhari S, Morgenstern R, Weinberg R, Kinkhabwala M, Panagiotou D, Castano A, DeLuca A, Kontak A, Jin Z, Maurer MS. Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. J Nucl Cardiol. 2018;25:181–190. 
• Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging. Predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880-889.
• Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017 Dec;84(12 Suppl 3):12-26.
• Falk RH. Cardiac Amyloidosis: A treatable disease, often overlooked. Circulation 2011;124:1079–1085. 
• Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AWJM, Rezk T, Fontana M, Palladini G, Miliani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133(24):2404-2412. 
• Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017;135:1357-1377. 
• Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Day T, Drachman BM, Shah SJ. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Eng J Med. 2018; 379:1007-1016. 
• Ruberg FL and Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286-1300. 
• Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164:222-228. 
• Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28:10-21. 
• Vranian MN, Sperry BW, Valent J, Hanna M. Emerging advances in the management of cardiac amyloidosis. Curr Cardiol Rep. 2015;17:100. 
• White JA and Fine NM. Recent advances in cardiovascular imaging relevant to the management of patients with suspected cardiac amyloidosis. Curr Cardiol Rep. 2016;18:77.

Partner Resources

Amyloidosis Foundation